Cargando…

Efficacy of two once-daily methylphenidate formulations compared across dose levels at different times of the day: Preliminary indications from a secondary analysis of the COMACS study data

BACKGROUND: Methylphenidate (MPH) is commonly prescribed in the treatment of Attention-Deficit/Hyperactivity Disorder or ADHD. Concerta and Metadate CD are once-daily formulations of MPH using different delivery mechanisms resulting in different pharmacokinetic profiles. A recent study (COMACS) show...

Descripción completa

Detalles Bibliográficos
Autores principales:	Sonuga-Barke, Edmund JS, Swanson, James M, Coghill, David, DeCory, Heleen H, Hatch, Simon J
Formato:	Texto
Lenguaje:	English
Publicado:	BioMed Central 2004
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC524494/ https://www.ncbi.nlm.nih.gov/pubmed/15458569 http://dx.doi.org/10.1186/1471-244X-4-28

Ejemplares similares

An inventory of European data sources for the long-term safety evaluation of methylphenidate
por: Murray, Macey L., et al.
Publicado: (2013)

Effectiveness and safety of a long-acting, once-daily, two-phase release formulation of methylphenidate (Ritalin(®) LA) in school children under daily practice conditions
por: Haertling, Fabian, et al.
Publicado: (2014)

Methylphenidate-Related Improvements in Math Performance Cannot Be Explained by Better Cognitive Functioning or Higher Academic Motivation: Evidence From a Randomized Controlled Trial
por: Kortekaas-Rijlaarsdam, Anne Fleur, et al.
Publicado: (2017)

CoMAC: A cooperation-based multiparty audio conferencing system for mobile users
por: Wang, Sheng-Shih, et al.
Publicado: (2022)

Development of a non-settling gel formulation of 0.5% loteprednol etabonate for anti-inflammatory use as an ophthalmic drop
por: Coffey, Martin J, et al.
Publicado: (2013)

An observational study of once-daily modified-release methylphenidate in ADHD: effectiveness on symptoms and impairment, and safety
por: Döpfner, Manfred, et al.
Publicado: (2011)

DRD4 and DAT1 in ADHD: Functional neurobiology to pharmacogenetics
por: Turic, Darko, et al.
Publicado: (2010)

Development of the CoMac Adherence Descriptor™: a linguistically-based survey for segmenting patients on their worldviews
por: Connor, Ulla M, et al.
Publicado: (2015)

Once– versus twice–daily tacrolimus: are the formulations equivalent?
por: Ciszek, Michał
Publicado: (2013)

More to ADHD than meets the eye: Observable abnormalities in search behaviour do not account for performance deficits on a discrimination task
por: Sonuga-Barke, Edmund JS, et al.
Publicado: (2005)

An observational study of once-daily modified-release methylphenidate in ADHD: quality of life, satisfaction with treatment and adherence
por: Rothenberger, Aribert, et al.
Publicado: (2011)

Editorial: Attention and Methylphenidate
por: Avital, Avi, et al.
Publicado: (2020)

Distinguishing low frequency oscillations within the 1/f spectral behaviour of electromagnetic brain signals
por: Demanuele, Charmaine, et al.
Publicado: (2007)

Spontaneous activity in the waiting brain: A marker of impulsive choice in attention-deficit/hyperactivity disorder?
por: Hsu, Chia-Fen, et al.
Publicado: (2015)

Cardiovascular Effects of Stimulant and Non-Stimulant Medication for Children and Adolescents with ADHD: A Systematic Review and Meta-Analysis of Trials of Methylphenidate, Amphetamines and Atomoxetine
por: Hennissen, Leonie, et al.
Publicado: (2017)

The reinforcing value of delay escape in attention deficit/hyperactivity disorder: An electrophysiological study
por: Chronaki, Georgia, et al.
Publicado: (2019)

An electrophysiological investigation of reinforcement effects in attention deficit/hyperactivity disorder: Dissociating cue sensitivity from down-stream effects on target engagement and performance
por: Chronaki, Georgia, et al.
Publicado: (2017)

Loteprednol etabonate (submicron) ophthalmic gel 0.38% dosed three times daily following cataract surgery: integrated analysis of two Phase III clinical studies
por: Fong, Raymond, et al.
Publicado: (2019)

In Vitro Time-Kill of Common Ocular Pathogens with Besifloxacin Alone and in Combination with Benzalkonium Chloride
por: Blondeau, Joseph, et al.
Publicado: (2021)

Chronic non-cancer pain: Focus on once-daily tramadol formulations
por: Coluzzi, Flaminia, et al.
Publicado: (2007)

On the Reorganization of Incentive Structure to Promote Delay Tolerance: A Therapeutic Possibility for AD/HD?
por: Sonuga-Barke, Edmund J. S.
Publicado: (2004)

‘If it don't fit, don't force it?’ If real‐world, complex clinical decisions are intrinsically categorical can dimensional systems add value? Reflections on Lahey, Tiemeier & Krueger (2022)
por: Sonuga‐Barke, Edmund J. S.
Publicado: (2022)

Effects of Converting Tacrolimus Formulation from Twice-Daily to Once-Daily in Liver Transplantation Recipients
por: Thorat, Ashok, et al.
Publicado: (2014)

Preschool hyperactivity is associated with long‐term economic burden: evidence from a longitudinal health economic analysis of costs incurred across childhood, adolescence and young adulthood
por: Chorozoglou, Maria, et al.
Publicado: (2015)

Long-acting methylphenidate formulations in the treatment of attention-deficit/hyperactivity disorder: a systematic review of head-to-head studies
por: Coghill, David, et al.
Publicado: (2013)

Formulation and Evaluation of Once Daily Minocycline Hydrochloride Extended Release Matrix Tablets
por: Keny, R. V., et al.
Publicado: (2009)

The Effect of Once-Daily Gabapentin Extended Release Formulation in Patients With Postamputation Pain
por: Knezevic, Nebojsa Nick, et al.
Publicado: (2019)

Pharmacokinetics and Safety of a Bilastine Once-Daily, Preservative-Free, Ophthalmic Formulation
por: Ochoa, Dolores, et al.
Publicado: (2021)

Advances in Corticosteroid Therapy for Ocular Inflammation: Loteprednol Etabonate
por: Comstock, Timothy L., et al.
Publicado: (2012)

The Role of Nitric Oxide in the Intraocular Pressure Lowering Efficacy of Latanoprostene Bunod: Review of Nonclinical Studies
por: Cavet, Megan E., et al.
Publicado: (2018)

Antibiotic resistance among bacterial conjunctival pathogens collected in the Antibiotic Resistance Monitoring in Ocular Microorganisms (ARMOR) surveillance study
por: Asbell, Penny A., et al.
Publicado: (2018)

Erratum to: Long-acting methylphenidate formulations in the treatment of attention-deficit/hyperactivity disorder: a systematic review of head-to-head studies
por: Coghill, David, et al.
Publicado: (2015)

Effects of long-term methylphenidate use on growth and blood pressure: results of the German Health Interview and Examination Survey for Children and Adolescents (KiGGS)
por: McCarthy, Suzanne, et al.
Publicado: (2018)

A Comparative Analysis of Once-daily and Twice-daily Formulation of Tacrolimus in De Novo Kidney Transplant Recipients
por: Ferhatoglu, Murat Ferhat, et al.
Publicado: (2021)

Clinical, Experimental, and Modeling Studies in AD/HD
por: Sonuga-Barke, Edmund J. S., et al.
Publicado: (2004)

Once-daily topical treatment for psoriasis: calcipotriene + betamethasone two-compound topical formulation
por: Shepherd, Jonisha, et al.
Publicado: (2013)

Population pharmacokinetics and pharmacogenetics of once daily tacrolimus formulation in stable liver transplant recipients
por: Moes, D. J. A. R, et al.
Publicado: (2015)

Estimation of brain receptor occupancy for trazodone immediate release and once a day formulations
por: Oggianu, Laura, et al.
Publicado: (2022)

An observational study of once-daily modified-release methylphenidate in ADHD: the effect of previous treatment on ADHD symptoms, other externalising symptoms and quality-of-life outcomes
por: Döpfner, Manfred, et al.
Publicado: (2011)

In Vitro Inhibition of Evaporation with Perfluorohexyloctane, an Eye Drop for Dry Eye Disease
por: Vittitow, Jason, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_agc04h6vaf8skhor43im0p9qdc